| URL | https://www.contractpharma.com/contents/view_break |
| Source | Contract Pharma |
| Date Published | 04/12/2022 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Achilles Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | King of Prussia, |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |